Articles with public access mandates - Gilles SallesLearn more
Not available anywhere: 13
Review
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger …
O Hermine, E Hoster, J Walewski, A Bosly, S Stilgenbauer, C Thieblemont, ...
The Lancet 388 (10044), 565-575, 2016
Mandates: Lymphoma Research Foundation, USA
Review
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
S Amorim, A Stathis, M Gleeson, S Iyengar, V Magarotto, X Leleu, ...
The Lancet Haematology 3 (4), e196-e204, 2016
Mandates: National Institute for Health Research, UK
Review
t (14; 18) Translocation: A predictive blood biomarker for follicular lymphoma
S Roulland, RS Kelly, E Morgado, S Sungalee, P Solal-Celigny, ...
Journal of clinical oncology 32 (13), 1347-1355, 2014
Mandates: National Institute of Health and Medical Research, France, Swedish Research …
Review
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
M Pfeifer, B Zheng, T Erdmann, H Koeppen, R McCord, M Grau, A Staiger, ...
Leukemia 29 (7), 1578-1586, 2015
Mandates: German Research Foundation
Review
Gray-zone lymphoma between cHL and large B-cell lymphoma: a histopathologic series from the LYSA
C Sarkozy, C Copie-Bergman, D Damotte, S Ben-Neriah, B Burroni, ...
The American Journal of Surgical Pathology 43 (3), 341-351, 2019
Mandates: National Institute of Health and Medical Research, France
Review
High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European …
O Hermine, L Jiang, J Walewski, A Bosly, C Thieblemont, M Szymczyk, ...
Journal of clinical oncology 41 (3), 479-484, 2023
Mandates: Lymphoma Research Foundation, USA
Review
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study
H Tilly, F Morschhauser, O Casasnovas, TJ Molina, P Feugier, S Le Gouill, ...
The Lancet Haematology 5 (9), e403-e410, 2018
Mandates: National Institute of Health and Medical Research, France
Review
CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas
KN Fitzgerald, AE Quesada, G von Keudell, S Raj, NE Lewis, A Dogan, ...
Leukemia & Lymphoma 63 (3), 751-754, 2022
Mandates: US National Institutes of Health
Review
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries
GP Collins, A Rueda, G Salles, B von Tresckow, F Zaja
Leukemia & Lymphoma 59 (9), 2113-2120, 2018
Mandates: National Institute for Health Research, UK
Review
The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome
WW Chien, R Catallo, A Chebel, L Baranger, X Thomas, MC Béné, ...
Leukemia Research 39 (4), 453-461, 2015
Mandates: Swiss Cancer League
Review
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY.
AF Herrera, S Tracy, LH Sehn, F Jardin, G Lenz, M Trněný, G Salles, ...
Hematological Oncology 41, 2023
Mandates: Swiss Cancer League
Review
IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY.
LJ Nastoupil, G Hess, MA Pavlovsky, I Danielewicz, J Freeman, ...
Hematological Oncology 41, 2023
Mandates: US National Institutes of Health
Review
BENDAMUSTINE, RITUXIMAB, AND POLATUZUMAB VEDOTIN FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: SINGLE‐CENTER REAL‐WORLD EXPERIENCE
KA Farina, E Drill, LW Buie, L Falchi, A Kumar, A Noy, ML Palomba, ...
Hematological Oncology 39, 2021
Mandates: US National Institutes of Health, National Institute of Health and Medical …
Available somewhere: 172
Review
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert, ...
Blood, The Journal of the American Society of Hematology 127 (20), 2375-2390, 2016
Mandates: US National Institutes of Health
Review
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
Mandates: US National Institutes of Health
Review
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ...
Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022
Mandates: US National Institutes of Health
Review
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
Mandates: US National Institutes of Health, National Institute for Health Research, UK …
Review
Diffuse large B-cell lymphoma
LH Sehn, G Salles
New England Journal of Medicine 384 (9), 842-858, 2021
Mandates: US National Institutes of Health
Review
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase …
JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ...
The Lancet 395 (10232), 1278-1291, 2020
Mandates: US National Institutes of Health
Review
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
C Charlier, É Perrodeau, A Leclercq, B Cazenave, B Pilmis, B Henry, ...
The Lancet Infectious Diseases 17 (5), 510-519, 2017
Mandates: National Institute of Health and Medical Research, France
Publication and funding information is determined automatically by a computer program